Page 64 - Boxed Warning News Today

Allergan, an ABBVie company, today announced that the U.S. Food and Drug Administration has approved BOTOX ® for the treatment of detrusor overactivity associated with a neurologic condition in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication. Neurogenic detrusor overactivity occurs when the spinal cord and bladder are not able to … – Allergan, an ABBVie (NYSE: ABBV) company, today announced that the U.S. Food a...

Tuesday, February 9, 2021 The Food and Drug Administration (FDA) and the National Telecommunications Information Administration (NTIA) in partnership with three domain name registries disabled nearly 30 websites illegally offering opioids for sale. Working together as part of a pilot program jointly created by the Department of Health and Human Services (HHS) and the Department of Commerce (Commerce), FDA and NTIA aim to reduce the availability of unapproved and misbranded opioids ill...

FDA issues alert over arthritis, ulcerative colitis medicine Trial shows increased risk of heart-related problems, cancer Published:  Tags:  WASHINGTON – The U.S. Food and Drug Administration is alerting the public about an increased risk of serious heart-related problems and cancer with the arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib) compared to another type of medicine called tumor necrosis factor (TNF) inhibitors. The FDA required the safety trial, which a...

Sorry, but your browser does not support the video tag.

Press release content from Business Wire. The AP news staff was not involved in its creation. Merck Announces U.S. FDA Approval of VERQUVO® (vericiguat) January 20, 2021 GMT KENILWORTH, N.J.--(BUSINESS WIRE)--Jan 20, 2021-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved VERQUVO, a soluble guanylate cyclase (sGC) stimulator, to reduce the risk of cardiovascular death and heart failure hospitaliza...

Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference - BOTOX® (onabotulinumtoxinA) and BOTOX Cosmetic® clinical data across multiple therapeutic and aesthetic indications - New analyses from CD-PROBE study evaluating sustained efficacy and tolerability of onabotulinumtoxinA in patients with cervical dystonia - New analyses from the ASPIRE study on patient adhe...

Radius Health Announces Commercial Agreement with Paladin Labs for Abaloparatide in Canada Agreement incorporates TYMLOS ® and abaloparatide-TD Consideration includes upfront payment, milestones based on clinical, regulatory and commercial progression, as well as royalties Key first step in expanding the global footprint for the abaloparatide asset beyond the U.S. and Japan; a key focus area for the company for 2021 BOSTON, Jan. 05, 2021 — Radius Health, Inc. (“Radius” or the “Compa...

Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA® (naxitamab-gqgk) and Omburtamab in Eastern Europe December 18, 2020 09:00 ET | Source: Y-mAbs Therapeutics, Inc Y-mAbs Therapeutics, Inc New York, UNITED STATES NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, anti...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA® (naxitamab-gqgk) and Omburtamab in ... Y-mAbs Therapeutics, IncDecember 18, 2020 GMT NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic produ...

Takeda Pharmaceutical Company Limited U.S. FDA Approves Supplemental New Drug Application for Takeda’s ICLUSIG® (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CML Saturday, December 19, 2020 2:19PM IST (8:49AM GMT)    – Updated ICLUSIG Label will Prove Practice-Changing, Expanding Indication to CP-CML Patients with Resistance or Intolerance to At Least Two Prior Tyrosine Kinase Inhibitors (TKIs) – ­– Approval Based on Data from the Phase 2 OPTIC Trial, W...